Yellow fever vaccine
Conditions
Interventions
V03.175.500
This is a cross-sectional, comparative, observational study conducted in children and adults of both genders that received the 17DD yellow fever primary vaccination employing a reduced dose in 2018, a
10-49 years
=50 years). Actually, 8 years after primary vaccination, the volunteers will be 10-19 years
20-59 years
=60 years. The sample size was estimated as a non-probabilistic convenience sample for monitoring volunteers 8 years after 17DD yellow fever primary vaccination using a reduced dose and that did not
A11.118.637.555.567.269.750
A11.063.438.450.650
Sponsors
Instituto René Rachou da Fundação Oswaldo Cruz
Instituto Nacional de Infectologia Evandro Chagas da Fundação Oswaldo Cruz
Eligibility
Age
10 Years to No maximum
Inclusion criteria
Inclusion criteria: Female and male participants; who participated in the study “Humoral and cellular immunity in children and adults subjected to 17DD yellow fever primary vaccination with a fractional dose,” conducted in the state of São Paulo in 2018; who had a negative yellow fever seroneutralization result prior to vaccination in 2018; participants must be at least 10 years old in 2025; participants must agree to provide their name, address, telephone number, and other personal information to allow contact; participants must be able to understand and sign the assent form or the informed consent form
Exclusion criteria
Exclusion criteria: Participants who received another dose of the yellow fever vaccine after 2018 with confirmation in the immunization record; participants diagnosed with autoimmune diseases or neoplasms after 2018, or who are using immunomodulatory drugs; participants presenting with a febrile illness at the time of sample collection; participants who have received the dengue or cholera vaccine; participants who were diagnosed with yellow fever after vaccination in 2018
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find neutralizing antibody titers in children and adults vaccinated primarily using the fractional dose (1/5 of the standard dose) of the 17DD yellow fever vaccine, similar to the neutralizing antibody titers in children and adults vaccinated primarily using the standard dose | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find a profile of memory T and B cells, induced in vitro by the yellow fever antigen and an immunological pattern of soluble mediators hildren and adults primary vaccinated using 17DD yellow fever the reduced dose vaccine, like that of children and adults primary vaccinated using the standard dose | — |
Countries
Brazil
Contacts
Public ContactOlindo Martins-Filho
Instituto René Rachou da Fundação Oswaldo Cruz
Outcome results
None listed